1. Home
  2. WETH vs NXTC Comparison

WETH vs NXTC Comparison

Compare WETH & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WETH

Wetouch Technology Inc.

HOLD

Current Price

$1.20

Market Cap

15.0M

Sector

N/A

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$8.00

Market Cap

17.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WETH
NXTC
Founded
1992
2015
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
17.3M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
WETH
NXTC
Price
$1.20
$8.00
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
53.2K
199.4K
Earning Date
04-13-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
15.38
N/A
EPS
0.50
N/A
Revenue
$45,136,818.00
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.40
N/A
Revenue Growth
6.76
N/A
52 Week Low
$0.92
$1.55
52 Week High
$3.68
$15.74

Technical Indicators

Market Signals
Indicator
WETH
NXTC
Relative Strength Index (RSI) 50.74 65.26
Support Level $1.14 $3.98
Resistance Level $1.49 $8.72
Average True Range (ATR) 0.06 0.70
MACD 0.00 0.01
Stochastic Oscillator 45.45 81.19

Price Performance

Historical Comparison
WETH
NXTC

About WETH Wetouch Technology Inc.

Wetouch Technology Inc is a business of research and development, manufacturing, and distribution of touchscreen displays to customers both in the PRC and overseas. The touchscreen products, which are manufactured by the Company, are mainly for use in financial terminals, automotive, Point of Sales, gaming, lottery, medical, Human-Machine Interface (HMI), and other specialized industries. The company sells touchscreen products both domestically in China and internationally, covering areas in Mainland China, including but not limited to the eastern, southern, northern, and southwest regions of Mainland China, Taiwan, South Korea, Germany, and other countries.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: